Check out these fastest-growing small-cap healthcare stocks

Be the First to Comment Read

Check out these fastest-growing small-cap healthcare stocks

 Check out these fastest-growing small-cap healthcare stocks
Image source: Hparatlala,Shutterstock

Highlights

  • Xencor, Inc. (Nasdaq: XNCR) reported revenue of US$67.4 million in Q2, 2021.
  • Healthcare Services Group, Inc (Nasdaq: HCSG) reported a gross profit of US$61.8 million in Q2, 2021.
  • Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recorded a net income of US$14.12 million in Q2, 2021.

Growth stocks are companies that report higher sales and revenue than the average growth of the sector. These companies generally have a higher P/E ratio, unique products, technology, or patent in their name. Small-cap companies typically have a market cap of US$300 million to US$2 billion.

The healthcare sector comprises companies that produce and sell drugs, provides insurance health cover, or run hospital chains, etc. Here we explore some of the fastest-growing small-cap healthcare companies.

                     

Fastest growing Small cap Healthcare Stocks to Watch Out

 

Xencor, Inc. (Nasdaq: XNCR)

The stock of this biopharmaceutical company traded at US$31.96 at 1.53 pm ET on August 17, up 0.63 percent from the August 16 closing price. The stock price of XNCR fell by 26.56 percent YTD. The P/E ratio is 86.58.

The market capitalization of this clinical-stage research company is US$1.8 billion. The forward P/E one year is -42.35. The EPS is US$0.37. The highest and the lowest stock price of XNCR for the past 52 weeks were US$58.54 and US$30.20.

The total revenue of the healthcare company for Q2 this year was US$67.4 million against US$13.1 million of Q2 the previous year. The net income for Q2 this year was US$52.2 million against losses of US$35 million in Q2 the previous year.

Also read: Top mid-cap pharma stocks powering the NASDAQ Biotech Index

Source: Pixabay.

Healthcare Services Group, Inc (Nasdaq: HCSG)

The stock of the healthcare company traded at US$25.97 at 1.59 pm ET on August 17, down 1.81 percent from the August 16 closing price. The stock value of HCSG fell by 7.56 percent YTD. The P/E ratio is 21.57.

The total revenue of HSCG in Q2, 2021, was US$98.2 million against US$452 million in Q2 last year. The gross profit in Q2, 2021, and Q2, 2020, were US$61.8 million and US$64.5 million, respectively. The net income in the latest quarter was US$9.6 million against US$23.1 million in Q2 last year.

The market capitalization of the company is US$1.9 billion. The forward P/E one year is 23.62. The EPS is US$1.20, and the annual dividend is US$0.835. The highest and the lowest stock price of HCSG in the past 52 weeks was US$35.80 and US$20.05.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY)

The stock of the pharmaceutical company traded at US$31.77 at 2.18 pm ET on August 17, up 0.83 percent from the August 16 closing price. The stock value of HRMY fell by 12.23 percent YTD. The P/E ratio is 138.04.

The total revenue of the healthcare company in Q2, 2021, was US$73.82 million against US$38.01 million in the year-ago quarter. The gross profit for Q2, 2021, was US$61.13 million against US431.55 million in Q2 last year. The net income for the period was US$14.12 million against losses of US$0.3 million in Q2 the previous year.

The market capitalization of the company is US$1.8 billion. The forward P/E one year is 30.30. The EPS is US$0.23. The highest and the lowest stock price of HRMY for the past 52 weeks was US$52.74 and US$25.09.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND)

The stock of this biotechnology company traded at US$106.675 at 2.31 pm ET on August 17, down 0.54 percent from the August 16 closing price. The stock value of LGND went up by 9.90 percent YTD. The P/E ratio is 38.6.

The market capitalization of LGND is US$1.7 billion. The forward P/E one year is 24.94. The EPS is US$2.77. The highest and the lowest stock price of LGND in the past 52 weeks was US$219.75 and US$78.26.

The total revenue of the medical research company in Q2, 2021, was US$84.64 million against US$41.42 million in Q2 the previous year. The gross profit for the period was US$54.08 million compared to US$33.78 million in Q2 last year. The net income in Q2 this year was US$30.73 million against US$22.09 million in Q2 last year.


 

Source: Pixabay.

Avanos Medical, Inc. (NYSE: AVNS)

The stock of the medical equipment company traded at US$33.88 at 2.53 pm ET on August 17, up 0.18 percent from the August 16 closing price. The stock value of AVNS went down by 26.210 percent YTD. The P/E ratio is 1129.67.

The market capitalization of the company is US$1.6 billion. The forward P/E one year is 29.16. The EPS is US$0.03. The highest and the lowest stock price of AVNS for the past 52 weeks was US$53.61 and US$30.92. 

Total revenue of the medical technology company in Q2 this year was US$186.4 million against US$163.7 million in Q2 the previous year. The gross profit for the period was US$85.7 million compared to US$86.5 in Q2 last year. The net income in Q2, 2021, was US$37.9 million against US$3 million losses in Q2 the previous year.

Also read: Why are these four pharma stocks drawing investors’ attention?

US Physical Therapy, Inc. (NYSE: USPH)

The stock of the healthcare facilities company traded at US$112.53 at 3.03 pm ET on August 17, up 0.24 percent from the August 16 closing price. The stock value of USPH went down by 6.87 percent YTD. The P/E ratio is 48.25.

The market capitalization of the healthcare services company is US$1.4 billion. The forward P/E one year is 36.10. The EPS is US$2.32, and the annual dividend is US$1.52. The highest and the lowest stock price of USPH for the past 52 weeks was US$143.67 and US$74.79. 

The total revenue of the company in Q2 this year was US$126.9 million against US$83.9 million in Q2 the previous year. The gross profit for the period was US$34.3 million compared to US$19.4 in Q2 last year. The net income of the surgical management company in Q2, 2021, was US$12.4 million against US$10.2 million losses in Q2 the previous year.

Bottomline

The coronavirus pandemic proved to be a blessing in disguise for many healthcare companies. The sector is expected to grow further in the coming months as the demand for various health services is also projected to grow.

Disclaimer

Speak your Mind

Featured Articles